A
Andrew Worden
Researcher at Miltenyi Biotec
Publications - 13
Citations - 461
Andrew Worden is an academic researcher from Miltenyi Biotec. The author has contributed to research in topics: Chimeric antigen receptor & CD19. The author has an hindex of 5, co-authored 12 publications receiving 205 citations.
Papers
More filters
Journal ArticleDOI
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Nirav N. Shah,Bryon D. Johnson,Dina Schneider,Fenlu Zhu,Aniko Szabo,Carolyn A. Keever-Taylor,Winfried Krueger,Andrew Worden,Michael Kadan,Sharon Yim,Ashley M. Cunningham,Mehdi Hamadani,Timothy S. Fenske,Boro Dropulic,Rimas J. Orentas,Rimas J. Orentas,Parameswaran Hari +16 more
TL;DR: On-site manufacturing and infusion of non-cryopreserved LV20.19 CAR T cells were feasible and therapeutically safe, showing low toxicity and high efficacy, and loss of the CD19 antigen was not seen in patients who relapsed or experienced treatment failure.
Journal ArticleDOI
Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model.
Kim Anthony-Gonda,Ariola Bardhi,Alex K. Ray,Nina C. Flerin,Mengyan Li,Weizao Chen,Christina Ochsenbauer,John C. Kappes,John C. Kappes,Winfried Krueger,Andrew Worden,Dina Schneider,Zhongyu Zhu,Rimas Orentas,Dimiter S. Dimitrov,Harris Goldstein,Boro Dropulic +16 more
TL;DR: It is shown that transduction with lentiviral vectors encoding multispecific anti-HIV duoCARs confer primary T cells with the capacity to potently reduce cellular HIV infection by up to 99% in vitro and >97% in vivo, and this data suggest that mult ispecificAnti-Hiv duoCAR-T cells could be an effective approach for the treatment of patients with HIV-1 infection.
Journal ArticleDOI
Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma
Zachary Jackson,Anne Roe,Ashish Sharma,Filipa Blasco Tavares Pereira Lopes,Aarthi Talla,Sarah Kleinsorge-Block,Kayla Zamborsky,Jennifer Schiavone,Shivaprasad Manjappa,Robert Schauner,Grace Lee,Ruifu Liu,Paolo Caimi,Ying Xiong,Winfried Krueger,Andrew Worden,Mike Kadan,Dina Schneider,Rimas J. Orentas,Rimas J. Orentas,Boro Dropulic,Rafick-Pierre Sekaly,Marcos de Lima,David N. Wald,David N. Wald,Jane S. Reese,Jane S. Reese +26 more
TL;DR: It is hypothesized that point of care manufacturing of CAR-T cells on the automated CliniMACS Prodigy device allows reproducible and fast delivery of cells for the treatment of patients with non-Hodgkin lymphoma.
Journal ArticleDOI
Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.
Nirav N. Shah,Fenlu Zhu,Dina Schneider,Carolyn Taylor,Winfried Krueger,Andrew Worden,Walter L. Longo,Mehdi Hamadani,Timothy S. Fenske,Bryon D. Johnson,Boro Dropulic,Rimas Orentas,Parameswaran Hari +12 more
TL;DR: Anti-CD19 CAR-T cell therapy is a breakthrough treatment for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) and despite impressive outcomes, non-r...
Journal ArticleDOI
A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma
Nirav N. Shah,Fenlu Zhu,Carolyn Taylor,Dina Schneider,Winfried Krueger,Andrew Worden,Sharon Yim,Timothy S. Fenske,Mehdi Hamadani,Bryon D. Johnson,Boro Dropulic,Rimas Orentas,Parameswaran Hari +12 more
TL;DR: A Phase 1 clinical trial evaluating a first-in-human bispecific tandem CAR-T cell directed against both CD19 and CD20 (CAR-20) antigens for patients with R/R B-cell NHL to demonstrate feasibility and safety and eliminate third party shipping logistics.